BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial
AbstractObjectivesThe BCG vaccine, widely used in Brazil in new-borns, induces adjuvant protection for several diseases, including childhood virus infections. BCG activates monocytes and innate memory NK cells which are crucial for the antiviral immune response. Therefore, strategies to prevent COVID-19 in health workers (HW) should be carried out to prevent them becoming unwell so that they can continue to work during the pandemic. The hypothesis is that BCG will improve the innate immune response and prevent symptomatic infection or COVID-19 severity.The primary objective is to verify the effectiveness and safety of the ...
Source: Trials - October 26, 2020 Category: Research Source Type: clinical trials

Clinical Study of BCG Vaccine for Intradermal Injection
Condition:   Tuberculosis Interventions:   Biological: BCG vaccine 1(0.025mg/0.1ml/person);   Biological: BCG vaccine 2 (0.05mg/0.1ml/person);   Biological: BCG vaccine 3(0.075mg/0.1ml/person);   Biological: BCG vaccine 4 (0.075mg/0.1ml/person);   Biological: Placebo of BCG vaccine (0.1ml/person) Sponsor:   Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials